Health-related quality of life (HRQoL) from KEYNOTE-204: A phase III, randomized, open-label study of pembrolizumab (pembro) vs brentuximab vedotin (BV) in relapsed or refractory classical Hodgkin lymphoma (R/R cHL)

Creative Commons License

Zinzani P. L., Ramchandren R., Santoro A., Paszkiewicz-Kozik E., Gasiorowski R., Johnson N. A., ...Daha Fazla

ESMO Virtual Congress, ELECTR NETWORK, 19 Eylül - 18 Ekim 2020, cilt.31, (Özet Bildiri) identifier